161 related articles for article (PubMed ID: 37228591)
41. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.
Zoumalan CI; Agarwal M; Sadun AA
Graefes Arch Clin Exp Ophthalmol; 2005 May; 243(5):410-6. PubMed ID: 15565293
[TBL] [Abstract][Full Text] [Related]
42. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
Shen L; Chen H; Wei Q
Front Immunol; 2021; 12():621858. PubMed ID: 33936037
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
44. Optic neuropathy caused by orbital Kimura disease: A rare case report.
Tsai YE; Chen YH; Liu T; Chien KH; Hsu CK
Medicine (Baltimore); 2022 Sep; 101(37):e30750. PubMed ID: 36123864
[TBL] [Abstract][Full Text] [Related]
45. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
46. A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
Takatsuki K; Yanagihara T; Egashira A; Ogo N; Yoshizawa S; Sunami S; Asoh T; Maeyama T
Am J Case Rep; 2021 Apr; 22():e930286. PubMed ID: 33903584
[TBL] [Abstract][Full Text] [Related]
47. [Clinical analysis of radiation optic neuropathy].
Yang H; Wang W; Hu HL; Chen SD; Yi CX; Zhang XL
Zhonghua Yan Ke Za Zhi; 2011 Dec; 47(12):1071-5. PubMed ID: 22336114
[TBL] [Abstract][Full Text] [Related]
48. Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.
Isoda A; Miyazawa Y; Tahara K; Mihara M; Saito A; Matsumoto M; Sawamura M
Intern Med; 2020 Aug; 59(16):2041-2045. PubMed ID: 32389947
[TBL] [Abstract][Full Text] [Related]
49. Leukemic and Lymphomatous Optic Neuropathy: A Case Series.
Lee V; Farooq AV; Shah HA
J Neuroophthalmol; 2021 Dec; 41(4):e796-e802. PubMed ID: 34629409
[TBL] [Abstract][Full Text] [Related]
50. Optic neuropathy presumably caused by vincristine therapy.
Sanderson PA; Kuwabara T; Cogan DG
Am J Ophthalmol; 1976 Feb; 81(2):146-50. PubMed ID: 1251878
[TBL] [Abstract][Full Text] [Related]
51. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.
Gemelli M; Carbone M; Abbate MI; Mancin M; Zucchini N; Colonese F; Invernizzi P; Bidoli P; Cortinovis D
Immunotherapy; 2022 Mar; 14(4):175-181. PubMed ID: 34873918
[TBL] [Abstract][Full Text] [Related]
52. Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
Sirgi Y; Krochmal R; Fleury CM; Holmes M; Dewitt CA; Cardis M; Kim C
Clin Lung Cancer; 2022 Sep; 23(6):542-546. PubMed ID: 35701321
[TBL] [Abstract][Full Text] [Related]
53. Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic Neuropathy.
Sasaki S; Asahara D; Kaneko K; Komatsumoto S
Am J Case Rep; 2015 Jun; 16():357-60. PubMed ID: 26057570
[TBL] [Abstract][Full Text] [Related]
54. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
55. [Amiodarone-induced optic neuropathy: A rare side effect].
Arcani R; Pellerey M; Rouby F; Gobin N; Scapin J; Chagny M; Arnould T; Ambrosi P; Gayet S; Micallef J; Villani P; Daumas A
Rev Med Interne; 2019 Dec; 40(12):826-830. PubMed ID: 31561935
[TBL] [Abstract][Full Text] [Related]
56. A case of severe Pembrolizumab-induced neutropenia.
Barbacki A; Maliha PG; Hudson M; Small D
Anticancer Drugs; 2018 Sep; 29(8):817-819. PubMed ID: 29889673
[TBL] [Abstract][Full Text] [Related]
57. Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.
Sears CM; Azad AD; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2021 May-Jun 01; 37(3S):S157-S160. PubMed ID: 32976335
[TBL] [Abstract][Full Text] [Related]
58. [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome].
Lüke C; Dohmen C; Dietlein TS; Brunner R; Lüke M; Krieglstein GK
Klin Monbl Augenheilkd; 2007 Dec; 224(12):932-4. PubMed ID: 18260057
[TBL] [Abstract][Full Text] [Related]
59. Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy.
Ben Simon GJ; Syed HM; Syed H; Douglas R; Schwartz R; Goldberg RA; McCann JD
Ophthalmic Surg Lasers Imaging; 2006; 37(4):284-90. PubMed ID: 16898388
[TBL] [Abstract][Full Text] [Related]
60. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
